ClinicalTrials.gg
CompletedNCT01942122Updated Jan 27, 2022

DLBS1442 for The Treatment of Pain in Patients Suspected Endometriosis

A Phase 2/3 interventional study of DLBS1442 100 and Mefenamic acid in Endometrioma and Visual Analogue Pain Scale: Moderate or Severe Pain, sponsored by Dexa Medica Group. Completed at 3 sites in Indonesia. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2022-01-27.

Sponsored by Dexa Medica Group · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Female
01

Study summary

This is a 3-arm, prospective, randomized, double-blind, and controlled study of DLBS1442 for the treatment of pain in patients suspected endometriosis. It is hypothesized that the reduction of the composite-pain intensity (as measured by VAS) from baseline to the end of study (week 8th) resulting from administration of DLBS1442, regardless of the dosage regimen, is significantly greater than that of Control. In addition, the administration of DLBS1442 at higher dose also results in significantly greater reduction than that of DLBS1442 at lower dose and of Control.

Read the detailed description

There will be three groups of treatment by dosage regimen in this study. Eligible subjects will be randomized to receive any of the following regimens: 1) DLBS1442 at a dose of 3 x 100 mg daily, or 2) DLBS1442 at a dose of 3 x 200 mg daily; or 3) mefenamic acid at a dose of 3 x 500 mg daily. DLBS1442 will be taken every day along the study period (8 weeks), while mefenamic acid will only be taken for five (5) days during the menstrual period, i.e. day 1st to day 5th of menstrual period. Study treatment will be given at a standardized starting point for all subjects, i.e. on the first day of their respective menstrual periods. Clinical and laboratory examinations to evaluate the investigational drug's efficacy and safety will be performed at baseline and every 4-week interval throughout the study period.

02

Conditions studied

  • Endometrioma
  • Visual Analogue Pain Scale: Moderate or Severe Pain

Keywords

  • DLBS1442
  • Endometriosis
  • Pain
  • Visual Analogue Scale
  • Endometriosis Health Profile (EHP-30TM)
03

In context

Endometriosis

922 studies on the registry are indexed under Endometriosis; 268 are open to participants now.

This study's enrollment of 60 is below the median of 67 across 541 interventional studies indexed under Endometriosis.

Browse Endometriosis studies →

Lead sponsor

Dexa Medica Group is the lead sponsor of 44 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed before any trial related activities
  • Female of 18 - 50 years of age
  • Subjects suspected with cystic endometriosis or adenomyosis confirmed by transvaginal ultrasonography (or transrectal ultrasonography for unmarried subjects)
  • Presence of moderate or severe pain as shown by VAS score of at least 4 on at least one of the following pain: menstrual pain (dysmenorrhea), dyspareunia, non-menstrual pelvic pain, dysuria, dyschezia
  • Occurrence of at least 3 last sequential menstrual cycles of 21 - 35 days duration prior to screening

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • Patients with infertility who are willing to be pregnant
  • Using hormonal or other forms of hormonal therapy within the last 30 days
  • Being under therapy with systemic on a chronic or regular basis within the last 90 days
  • History or presence of suspected abnormalities
  • History of surgical treatment for endometriosis within 3 months prior to screening
  • History of hysterectomy or oophorectomy
  • Presence of clinical signs of sexually transmitted disease
  • Presence of unexplained uterine or cervical bleeding
  • Impaired liver function: serum > 2.5 times
  • Impaired renal function: serum creatinine >= 1.5 times upper limit of normal
  • Known or suspected allergy to similar products
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    DLBS1442 100

    DLBS1442 capsules 3x100 mg daily, taken every day along the study period

    Drug: DLBS1442 100

  • Experimental
    DLBS1442 200

    DLBS1442 capsules 3x200 mg daily, taken every day along the study period

    Drug: DLBS1442 200

  • Active comparator
    Mefenamic acid

    Mefenamic acid tablets 3 x 500 mg daily, only taken for five (5) days during the menstrual period, i.e. day 1st to day 5th of menstrual period.

    Drug: Mefenamic acid

Interventions

  • DrugDLBS1442 100

    Study treatment will be DLBS1442 capsules at a dose of 3x100 mg daily. DLBS1442 will be taken every day for 8 weeks (2 menstrual cycles).

    Also known as: Dismeno 100

  • Control will be mefenamic acid 500 mg tablets, administered 3 times daily for 5 days during the menstrual period, i.e. day 1st to day 5th of the menstrual period. The drug will be given within the 8 weeks of study period (2 menstrual cycles).

    Also known as: Pondex Forte

  • DrugDLBS1442 200

    Study treatment will be DLBS1442 capsules at a dose of 3x200 mg daily. DLBS1442 will be taken every day for 8 weeks (2 menstrual cycles).

    Also known as: Dismeno 200

06

What researchers measure

Primary outcomes

  1. Reduction of intensity (VAS) of composite-pain

    Reduction of the intensity of composite-pain (dysmenorrhea, dyspareunia, non-menstrual chronic pelvic pain, dysuria, dyschezia) as measured by Visual Analogue Scale (VAS).

    Time frame: Week 8

Secondary outcomes

  1. Reduction of the intensity of each pain (VAS)

    Reduction of the intensity of each pain (dysmenorrhea, dyspareunia, non-menstrual chronic pelvic pain, dysuria, dyschezia) as measured by Visual Analogue Scale (VAS).

    Time frame: Week 4, week 8

  2. Response rate

    Response rate is defined as percentage of subjects at the end of study experiencing a reduction of VAS score of \>= 3 or \>= 30% as compared to baseline, in each of the composite pain found at baseline (i.e. dysmenorrhea, dyspareunia, non-menstrual pelvic pain, dysuria, or dyschezia).

    Time frame: Week 8

  3. Improvement of quality of life

    Improvement of quality of life is measured by Endometriosis Health Profile (EHP-30) questionnaire score.

    Time frame: Week 4, week 8

  4. Serum CA-125

    Reduction in serum CA-125 level.

    Time frame: Week 8

  5. IL-6

    Change of IL-6

    Time frame: Week 8

  6. Number of rescue medication

    Number of rescue medication (pain relieving drug, i.e. ibuprofen 400 mg tablet) needed during the course of the study.

    Time frame: During the course of the study

  7. Pain-free period

    Time to the first day on which subjects take rescue medication.

    Time frame: During the course of the study

  8. Percentage or proportion of subjects who complete the study

    Percentage or proportion of subjects who complete the study (2 cycles).

    Time frame: Week 8

  9. ECG

    Electrocardiography.

    Time frame: Week 8

  10. Vital signs

    Vital signs measured include: blood pressure, heart rate, respiratory rate.

    Time frame: Week 4, week 8

  11. Liver function

    Liver function measured includes: serum ALT (SGPT), serum AST (SGOT), and alkaline phosphatase (AP).

    Time frame: Week 8

  12. Renal function

    Renal function measured includes: serum creatinine and blood urea nitrogen (BUN).

    Time frame: Week 8

  13. Routine hematology

    Routine hematology measured includes: hemoglobin, hematocrit, RBC, WBC, differentiation of WBC, and platelet count.

    Time frame: Week 8

  14. Adverse event

    Adverse event will be observed and managed along the study course.

    Time frame: During the course of the study

  15. Reduction of intensity (VAS) of composite-pain

    Reduction of the intensity of composite-pain (dysmenorrhea, dyspareunia, non-menstrual chronic pelvic pain, dysuria, dyschezia) as measured by Visual Analogue Scale (VAS).

    Time frame: 4 weeks

  16. hs-CRP

    Change in serum hs-CRP.

    Time frame: Week 8

07

Study locations

3 sites
  • Yasmin Clinic, Dr. Cipto Mangunkusumo Hospital (Kencana)
    Jakarta Pusat, Jakarta 10430, Indonesia
  • Department of Obstetrics and Gynecology, RSUP Persahabatan
    Jakarta Pusat, Jakarta, Indonesia
  • Department of Obstetrics and Gynecology RSUP Fatmawati
    Jakarta, Indonesia
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2015, a primary completion of Feb 2021 and a completion of Apr 2021. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2013
First posted
Sep 13, 2013
Start
Oct 2015
Primary completionActual
Feb 2021
CompletionActual
Apr 2021
Last update
Jan 27, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01942122
Lead sponsor
Dexa Medica Group
Responsible party
Sponsor
First posted
Sep 13, 2013
Start date
Oct 2015
Primary completion
Feb 2021
Completion
Apr 2021
Last update
Jan 27, 2022

Study contacts

Kanadi Sumapraja, SpOG(K), MD
principal investigator · Division of Reproductive, Endocrinology, and Infertility, Department of Obstetrics and Gynecology, Faculty of Medicine, University of Indonesia/Dr. Cipto Mangunkusumo Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion